The National Health Sciences Administration in my country has approved the 21-valent pneumococcal conjugate vaccine CAPVAXIVE developed by the American pharmaceutical company Merck for vaccination by adults over the age of 18 to prevent pneumonia and other serious infections caused by specific types of Streptococcus pneumoniae.
The National Health Sciences Administration in my country has approved the 21-valent pneumococcal conjugate vaccine CAPVAXIVE developed by the American pharmaceutical company Merck for vaccination by adults over the age of 18 to prevent pneumonia and other serious infections caused by specific types of Streptococcus pneumoniae.
🇺🇸 USA · Map
More on Radar
Want to see every report in real time?
Hundreds of sources worldwide, translated into your language, with alerts for what matters to you.
Sign up free Already have an account? Log in